The Role of GSK3 and its Reversal with GSK3 Antagonism in Everolimus Resistance

Pancreatic neuroendocrine tumors (panNETs) are often inoperable at diagnosis. The mTORC1 inhibitor everolimus has been approved for the treatment of advanced NETs. However, the regular development of resistance to everolimus limits its clinical efficacy. We established two independent everolimus-res...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Endocr Relat Cancer
Auteurs principaux: Prada, Elke Tatjana Aristizabal, Spöttl, Gerald, Maurer, Julian, Lauseker, Michael, Koziolek, Eva Jolanthe, Schrader, Jörg, Grossman, Ashley, Pacak, Karel, Beuschlein, Felix, Auernhammer, Christoph Joseph, Nölting, Svenja
Format: Artigo
Langue:Inglês
Publié: 2018
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7439002/
https://ncbi.nlm.nih.gov/pubmed/29895527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-18-0159
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires